In March 2021 Biomapas started an EU funded project „mHealth solution for COVID-19 disease research, monitoring and treatment“.
The main aim of the project – to develop an innovative eHealth system for the research of COVID-19 disease.
During the project implementation period, Biomapas seeks to create electronic solutions for the effective and innovative COVID-19 disease process observation. The created prototype will be tested in a hybrid clinical trial to ensure effectiveness and safety.
Project implementation period: March 2021 – February 2022.
The project is co-financed by European Regional Development Fund up to € 1 000 000.
The project is funded as the EU response to the COVID-19 pandemic.
In July 2020, Biomapas started an EU-funded project of research and development activities by creating an artificial intelligence (AI) tool for pharmacovigilance services.
The main aim of the project – to create a pharmacovigilance system based on artificial intelligence.
Biomapas plans to commercialize the prototype of the technology created during the project in the form of a new pharmacovigilance service, ensuring continuous improvement of drug safety. It is planned that this service will be available on the market within a few months after completing the project. The company hopes that the new service will allow it to gain a fairly significant market share in the global market.
Project implementation period: July 2020 – June 2023.
The project is co-financed by European Regional Development Fund up to € 1 093 434,66.
In January 2017, Biomapas became active in an EU-funded project of strengthening international competitiveness by raising awareness in foreign markets.
Biomapas attended eight International Events/Exhibitions to introduce its services to key market players for current cooperation and share business development strategies by creating relationships for future collaboration.
EU funding for the project was 50% of the costs.